• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

J&J will be separating into two distinct firms, but not right away.
By STEPHEN GUILFOYLE
Nov 12, 2021 | 11:39 AM EST
Stocks quotes in this article: GE, PFE, MRK, JNJ, ABBV, BMY

Breaking up. It's all the rage. Just days after industrial conglomerate General Electric (GE) announced that firm's future de-conglomerization, and less recently after fellow pharmaceutical giants Pfizer (PFE) and Merck (MRK) had spun out their respective consumer businesses, comes the next shoe to drop. Johnson & Johnson (JNJ) , the world's largest health products company by sales and employer of more than 136K human beings, announced that the longstanding member of the Dow Jones Industrial Average will be separating into two distinct firms, but not right away. More like in a year and a half to two years, which makes this equity trader/investor wonder if this news came out only because it was coming out and not because the time was right.

What gives? A push to simplify business direction in order to improve focus during complex times? Sure. Oh, it might be about unlocking value as well. Perhaps the sum of the parts might be greater than the whole, especially if the slowest growing, lowest margin portion of the broader business is set free.

The Story

The S&P 500 is up 24% year to date. PFE is up 35%. Johnson & Johnson reported the firm's third quarter performance about three weeks ago. The firm beat on the adjusted bottom line, missed on the GAAP bottom line, and missed on the top line, albeit on 10.7% annual growth. Sales of the firm's COVID vaccine badly missed expectations. The firm did boost guidance for current quarter revenue, but still not quite to where Wall Street was on that metric. However, JNJ did also increase current quarter guidance for adjusted EPS above Wall Street's consensus. No mention of a breakup.

This week, Johnson & Johnson won a court ruling on their request to halt tens of thousands of talc related lawsuits. The firm also agrees to provide its COVID vaccine to some of the most vulnerable people in the world through the COVAX Humanitarian Buffer. No mention in either case of a breakup.

The firm currently operates through three business lines... Pharmaceuticals, which provided 55% of the firm's revenue in 2020, Medical Devices, which drove 28% of revenue last year, and Consumer Health, the legacy business that you all know that drove only 17% of total revenues. This last business is the one being spun off. The larger two businesses will retain the Johnson & Johnson name. The smaller business, including brands such as Listerine, Tylenol, Band-Aid, Neutrogena, and Rogaine will most likely be spun off in less than two years in a tax-free transaction that will include a stock offering.

This action has nothing to do with the lawsuits alleging that the firm's famous baby powder caused cancer, according to outgoing CEO Alex Gorsky. Gorsky will be replaced by Joaquin Duato who will run the pharmaceutical and medical devices business. There has not yet been any announced leadership for the consumer-focused spin off.

The Chart

I have to admit that I don't like this chart. I don't like that the shares have given up the majority of their pre-opening surge and have now retreated all the way to their 200 day SMA. What happens next is truly crucial. While I see good reason to be in this name ahead of the split, I really think that you have at least a year to make that decision. While this is a solid firm that pays investors $4.24 (2.6% yield) just to hang out, I see better value elsewhere in the pharma space. That's why I have been in Pfizer and AbbVie (ABBV) (ABBV is +9% ytd, div yield of 4.84%) all year, and have traded in and out of both Merck (MRK) and Bristol-Myers Squibb (BMY) on opportunity.

Keep in mind that next year is another election year, and both houses of Congress will be in play. One thing both the left and the right agree on? Beating up the drug companies.

If one is long the shares or decides to get long here... one can write January 2023 $210 calls against the position for about $1.50. Might as well get paid something for a long dated way out of the money calls. Not much risk outside of capping a profit that one would readily agree to right now, there.

(AbbVie is a holding in the Action Alerts PLUS member club. Want to be alerted before AAP buys or sells ABBV? Learn more now.)

We're holding a Veterans Day Sale for our Action Alerts PLUS investment club. Get in on the conversation and get the latest investment ideas and trading strategies. For 48 hours, we're offering 30% off with this special sale. Click here and save $150.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long GE, PFE equity, Short GE puts.

TAGS: Investing | Stocks | Technical Analysis | Trading | Pharmaceuticals | Consumer Products

More from Investing

So Far My Tax-Loss Selling Recovery Strategy Is Paying Off Big-Time

Jonathan Heller
Feb 4, 2023 12:30 PM EST

Here's how I'm making out on these names that were down at the end of last year.

How to Trade an Irrational Market

James "Rev Shark" DePorre
Feb 4, 2023 10:00 AM EST

The crowd of investors is often irrational, but most of the time it's right.

3 New Dividend Aristocrats for 2023 -- And Your Portfolio

Bob Ciura
Feb 4, 2023 7:15 AM EST

New to this exclusive club, these names have proven effective long-term compounders of shareholder wealth and dividend income.

In a Week Full of Surprises, This Was the Market's Biggest

James "Rev Shark" DePorre
Feb 3, 2023 4:42 PM EST

We had the Fed's rate decision, jobs numbers, and mega-cap tech earnings land. But here's what was the wildest action.

3 High-Yield REITs for Safe Dividend Income

Bob Ciura
Feb 3, 2023 2:31 PM EST

These names have joined the ranks of the world's most elite dividend growth companies as Dividend Aristocrats and/or Dividend Kings.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • 02:10 PM EST REAL MONEY

    Fed Rate Decision

    Fed Lifts Benchmark Rate by 25 Basis Points, Sees ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login